OakChart

Ascendis Pharma A/S

ASNDHealthcare·Biotechnology·Denmark·Large·NASD·Nov 11 • 1:23 PM ET

257.36+0.77 (0.30%)
2026-11-11 19:23 CET
Market cap
16,851.11 USD m
Revenue, TTM
1,220.73 USD m
Net income, TTM
866.59 USD m
Free cash flow, TTM
388.83 USD m
EPS diluted, TTM
13.12
P/E
19.61
Compare

Price

ASND against its 20, 50 and 200-day averages
2050200beatearnings
200.00220.00240.00260.00280.002.2M4.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ASNDclose 257.3620-day 246.3750-day 242.55200-day 239.36257.3652w high

8.8% under the 52-week high of 282.15 on 9 Jul 2026. 52-week low 188.07 on 13 Nov 2025. Last 15 sessions, 10.4% high to low

Profile

ASND
52-week range, 74% of the way up
188.07282.15

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

IndexRUI
IPOJan 28, 2015
Beta0.38
ATR, 14d6.34
Rel volume0.57
Short float4.62%
Insider own1.16%
Inst own102.72%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap16.90B
Enterprise Value16.49B
Income866.59M
Sales1.22B
Book/sh25.01
Cash/sh14.14
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJan 28, 2015

Ratios

P/E19.61
Forward P/E25.43
PEG-
P/S13.84
P/B10.29
P/C18.20
P/FCF43.47
EV/EBITDA112.53
EV/Sales13.51
Quick Ratio2.32
Current Ratio2.99
Debt/Eq0.31
LT Debt/Eq0.27
Option/ShortYes / Yes

Earnings

EPS (ttm)13.12
EPS next Y10.12
EPS next Q0.88
EPS this Y484.55%
EPS next Y-37.31%
EPS next 5Y-
EPS past 3/5Y27.03% 14.76%
Sales past 3/5Y147.23% 152.45%
EPS Y/Y TTM379.16%
Sales Y/Y TTM128.41%
EPS Q/Q583.50%
Sales Q/Q120.22%
EarningsNov 12 BMO
EPS/Sales Surpr.91.14% 3.86%

Ownership

Insider Own1.16%
Insider Trans-2.49%
Inst Own102.72%
Inst Trans1.57%
ROA44.55%
ROE121.87%
ROIC41.62%
Gross Margin89.84%
Oper. Margin10.32%
Profit Margin70.99%
SMA204.46%
SMA506.10%
SMA2007.52%
Trades-

Technical

Shs Outstand65.67M
Shs Float64.91M
Short Float4.62%
Short Ratio4.19
Short Interest3.00M
52W High282.15 -8.79%
52W Low188.07 36.84%
Volatility2.83% 2.43%
ATR (14)6.34
RSI (14)63.20
Beta0.38
Rel Volume0.57
Avg Volume715.44K
Volume251,712

Performance

Perf Week-0.22%
Perf Month15.30%
Perf Quarter4.52%
Perf Half Y5.66%
Perf YTD20.69%
Perf Year27.94%
Perf 3Y185.06%
Perf 5Y66.04%
Perf 10Y1220.45%
Recom1.18
Target Price303.77
Prev Close256.59
Price257.36
Change %0.30%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 15, 2026DowngradeRRaymond JamesStrong Buy → Outperform$287+11.5%
Aug 27, 2026InitiatedHH.C. WainwrightBuy$345+34.1%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$319+24.0%
May 19, 2026InitiatedCCitigroupBuy$355+37.9%
Mar 16, 2026ResumedJJefferiesBuy
Jan 28, 2026InitiatedBBarclaysOverweight$342+32.9%
Nov 18, 2025InitiatedWWolfe ResearchPeer Perform$255-0.9%
Oct 17, 2025InitiatedRRaymond JamesStrong Buy$271+5.3%
Jul 03, 2025ResumedMMorgan StanleyOverweight$250-2.9%
May 05, 2025UpgradeMMorgan StanleyEqual-Weight → Overweight$250-2.9%

Peers

Mkt cap
TickerCompanyMkt cap
BMRNBiomarin Pharmaceutical Inc11.18B
BBIOBridgeBio Pharma Inc15.41B
MBXMBX Biosciences Inc2.82B
RYTMRhythm Pharmaceuticals Inc7.93B
NVONovo Nordisk ADR136.28B
INSMInsmed Inc26.19B
NBIXNeurocrine Biosciences Inc17.57B
RAREUltragenyx Pharmaceutical Inc1.69B
ALNYAlnylam Pharmaceuticals Inc21.13B
PFEPfizer Inc166.61B

Insider trading

latest 14 of 36
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bodenhoff MadsSVP & PAOSep 08 '26Option Exercise110.003,000330,0003,000Sep 09 05:04 PM
Bodenhoff MadsSVP & PAOSep 08 '26Sale270.193,000810,5700Sep 09 05:04 PM
Bodenhoff MadsOfficerSep 08 '26Proposed Sale270.193,000810,563Sep 08 04:16 PM
HOLTUG LARSDirectorSep 02 '26Sale264.1323662,3354,000Sep 03 04:09 PM
HOLTUG LARSDirectorSep 02 '26Proposed Sale264.1323662,335Sep 02 12:52 PM
BIENAIME JEAN JACQUESDirectorAug 14 '26Buy246.332,000492,6542,900Aug 18 09:02 PM
SMITH SCOTT THOMASEVP & Chief Financial OfficerJun 02 '26Buy219.0010021,9004,367Jun 02 04:25 PM
BIENAIME JEAN JACQUESDirectorMay 29 '26Buy223.12500111,562900Jun 01 04:11 PM
SMITH SCOTT THOMASEVP & Chief Financial OfficerMay 29 '26Buy223.3225055,8304,267Jun 01 04:10 PM
BIENAIME JEAN JACQUESDirectorMay 26 '26Buy237.8040095,120400May 27 04:05 PM
JENSEN FLEMMING STEENSee RemarksMay 11 '26Sale238.4919,4604,641,0210May 12 04:08 PM
JENSEN FLEMMING STEENOfficerMay 11 '26Proposed Sale238.4919,4604,641,022May 11 03:36 PM
SINGEL STINAOfficerMar 09 '26Proposed Sale240.003,782907,680Mar 09 05:30 PM
Bodenhoff MadsOfficerMar 06 '26Proposed Sale237.5310,0002,375,308Mar 06 04:21 PM

Held by

AUM
TickerCompanyAUM
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B
IBBiShares Biotechnology ETFAUM: 11.36B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
IWFiShares Russell 1000 Growth ETFAUM: 116.57B
SQSSapient Quality Select ETFAUM: 1.32B
VONGVanguard Russell 1000 Growth Index ETFAUM: 43.99B
FXHFirst Trust Health Care AlphaDEX FundAUM: 1.19B
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.64B
COWGPacer US Large Cap Cash Cows Growth Leaders ETFAUM: 2.21B

News

latest 14 of 200
  • Ascendis Pharma to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
  • Ascendis Faces Its First Clean Quarter After PRV Windfall As UVWell Ramp Takes Center Stage (Earnings Whispers)
  • Once-Weekly TransCon CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union (GlobeNewswire)
  • Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 (GlobeNewswire)
  • TransCon PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years (GlobeNewswire)
  • RBC Capital names top healthcare stocks as sector upgraded to overweight (Investing.com)
  • ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug (Stocktwits)
  • Once-Weekly TransCon CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children (GlobeNewswire)
  • Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 (GlobeNewswire)
  • Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls (The Fly) -9.49%
  • Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular Diseases (GlobeNewswire)
  • Ascendis Announces Planned $400 Million Share Repurchase Program (GlobeNewswire)
  • First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 (GlobeNewswire)
  • Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12-0.881--403.5116
2026Q22026-08-133.2621.7073.262391.12376.618
2026Q12026-05-0711.4540.19011.411289.69313.5316
2025Q42026-02-11-0.653-0.096-0.636293.9291.6116
2025Q32025-11-12-1.159-0.283-1.173247.64247.3515
2025Q22025-08-07-0.958-1.512-0.729184.55169.2715
2025Q12025-05-01-1.785-1.671-1.659114.04108.2114
2024Q42025-02-12-0.665-1.015-0.686180.74123.4114
2024Q32024-11-14-1.811-1.703-1.89460.9076.5313
2024Q22024-09-03-2.110-1.617-2.05439.7791.9711
2024Q12024-05-02-2.468-1.573-2.500102.8984.6911
2023Q42024-02-07-1.658-1.940-1.650148.27100.4812
2023Q32023-11-07-2.876-2.490-3.13647.9651.6013
2023Q22023-09-05-2.321-2.723-2.35150.9340.516
2023Q12023-04-27-2.184-2.921-2.12237.0623.7212
2022Q42023-02-16-3.955-2.905-3.77624.0720.5812

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.095-4.574-5.24714.5313.53
2020FY-9.903-9.061-9.4368.3210.66
2021FY-7.744-8.185-8.2788.607.28
2022FY-11.118-10.531-10.93154.7349.33
2023FY-9.213-9.485-9.247287.4240.54
2024FY-6.786-7.056-7.064377.91320.87
2025FY-4.465-3.980-4.451855.14847.94
2026FY-16.145--1,513
2027FY-10.121--2,215
2028FY-15.635--2,805
2029FY-19.297--3,344
2030FY-23.077--3,812

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-111813403.51352.07416.5
2026Q3S2026-10-301815404.1352.58417.1
2026Q3S2026-10-291814405.82351.74452.17
2026Q3S2026-10-281914404.97350.82450.99
2026Q3S2026-10-271924406.68352.31452.9
2026Q3S2026-10-231994408.4353.8454.81
2026Q3S2026-10-2018103408.33353.57454.52
2026Q3S2026-10-161893407.14353.54454.48
2026Q3S2026-10-141893406.67353.18454.01
2026Q3S2026-10-131893405.14351.92452.41
2026Q3S2026-10-091793404.35353.54419.08
2026Q3S2026-10-071793405.74354.81420.58
2026Q3S2026-09-2317102413.24360.95430.44
2026Q3S2026-09-1817103414.25361.83431.49

Estimate history

EPS, annual-4.151-3.736-5.247-9.436-8.278-10.931-9.247-7.064-4.24613.1241
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.054-1.894-0.686-1.659-0.729-1.173-0.63611.4113.522
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.72612.48314.977.9269.19353.783288.353393.347812.7251220.73
Period201720182019202020212022202320242025TTM
Sales, quarterly38.75563.532185.515106.25179.136249.658288.073288.505394.49
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual36.98442.13547.98653.7556.78356.03956.61459.84461.3865.673
Period201720182019202020212022202320242025MRQ
Shares, quarterly57.3559.7659.84460.37460.55461.09861.3862.11265.673
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,220.73812.73393.35288.3553.789.197.9314.9712.48
Cost of Goods Sold Incl. D&A124.07121.2360.2063.2428.0919.31---
Gross Profit1,096.65691.49333.14225.1125.69-10.11---
Selling, General and Administrative Excl. Other970.71845.29634.68717.61616.14523.90374.05261.24194.02
Research and Development315.81333.10324.02435.86387.53337.77289.09208.56164.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income125.95-153.79-301.54-492.49-590.45-534.01-376.90-253.75-182.57
Interest Expense245.4991.0270.8647.6436.794.622.191.370.00
Unusual Expense0.00119.15-4.19-15.8416.270.000.00--
Net Income Before Taxes127.79-258.40-382.03-492.72-588.67-468.05-466.99-235.20-153.57
Income Taxes-753.5517.365.247.905.65-0.43-0.25-0.26-0.46
Consolidated Net Income866.59-257.35-408.97-520.50-612.92-453.38-477.60-244.01-153.48
Net Income From Continuing Operations866.59-257.35-408.97-520.50-612.92-453.38-477.60-244.01-153.48
Net Income866.59-257.35-408.97-520.50-612.92-453.38-477.60-244.01-153.48
EPS (Recurring)12.68-2.87-7.12-9.44-10.73-8.28-9.44-5.25-3.74
EPS (Basic, Before Extraordinaries)13.87-4.25-7.06-9.25-10.93-8.28-9.44-5.25-3.74
EPS (Diluted)13.12-4.25-7.06-9.25-10.93-8.28-9.44-5.25-3.74
EBITDA146.51-133.82-282.37-472.05-571.58-515.82-366.13-246.27-181.54
Non-Operating Income (Expense)247.33105.56-13.8331.5754.8470.59-87.9119.9329.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense109.69102.2680.5956.2152.6161.6147.2832.7318.08
Price To Earnings Ratio18.5018.50-------
Price To Sales Ratio14.9315.9020.2624.59127.33801.491,065.05432.20206.20
Gross Margin89.8485.0884.6978.0747.77-110.00---
Operating Margin10.32-18.92-76.66-170.79-1,097.85-5,808.59-4,755.07-1,695.10-1,462.59
Net Margin70.99-31.67-103.97-180.51-1,139.63-4,931.56-6,025.53-1,630.03-1,229.53
Shares Outstanding65.6761.3859.8456.6156.0456.7853.7547.9942.14
Market Capitalization16,851.1116,851.118,227.217,121.646,823.707,651.768,908.746,614.492,621.38

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue394.49288.51288.07249.66179.14106.25185.5163.53
Cost of Goods Sold Incl. D&A36.9424.8931.9630.2940.0122.7518.6516.13
Gross Profit357.55263.62256.12219.37139.1383.50166.8747.40
Selling, General and Administrative Excl. Other285.00234.59244.60206.52199.14193.18166.46153.68
Research and Development85.3966.3388.0976.0079.3388.8882.4278.83
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income72.5529.0311.5212.85-60.02-109.680.41-106.28
Interest Expense16.4878.6872.1478.1937.4247.1431.5127.84
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes263.07-44.37-32.63-58.28-35.04-126.45-35.00-103.06
Income Taxes26.89-792.647.984.234.361.121.161.12
Consolidated Net Income240.65736.28-39.06-71.27-44.04-99.59-41.03-108.97
Net Income From Continuing Operations240.65736.28-39.06-71.27-44.04-99.59-41.03-108.97
Net Income240.65736.28-39.06-71.27-44.04-99.59-41.03-108.97
EPS (Recurring)3.5211.41-0.64-1.17-0.73-1.66-0.69-1.89
EPS (Basic, Before Extraordinaries)3.7411.94-0.64-1.17-0.73-1.66-0.69-1.89
EPS (Diluted)3.5211.41-0.64-1.17-0.73-1.66-0.69-1.89
EBITDA77.8633.9717.1317.55-55.13-104.905.18-101.47
Non-Operating Income (Expense)207.005.2827.997.0562.4130.37-3.9031.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense26.8427.7427.2127.8926.5221.0221.8122.28
Price To Earnings Ratio18.50-------
Price To Sales Ratio14.9314.6815.9016.7619.5223.7421.0224.24
Gross Margin90.6491.3788.9187.8777.6778.5989.9574.61
Operating Margin18.3910.064.005.15-33.50-103.230.22-167.28
Net Margin61.00255.21-13.56-28.55-24.58-93.73-22.12-171.52
Shares Outstanding65.6762.1161.3861.1060.5560.3759.8459.76
Market Capitalization16,851.1114,039.5213,028.5812,038.8210,420.479,327.228,227.218,562.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments723.51579.41441.24784.91775.64879.48671.37317.64234.58
Short Term Receivables185.21183.7461.6127.3526.378.996.083.012.85
Inventories354.14306.10230.80139.4685.750.000.000.000.00
Other Current Assets39.6029.2742.6233.8528.6917.128.5814.198.29
Total Current Assets1,302.451,098.52776.26985.57916.45905.59686.03334.84245.72
Net Property, Plant & Equipment172.03102.22122.21137.78143.34132.2850.594.943.07
Total Investments and Advances38.2014.066.2832.47165.92152.2817.4419.530.00
Long-Term Note Receivable12.772.402.352.05-----
Intangible Assets4.364.174.885.156.007.003.924.004.20
Other Assets0.000.000.000.002.061.681.641.320.35
Total Assets1,529.801,221.37911.981,163.021,233.771,198.83759.63364.63253.34
Short Term Debt Incl. Current Port. of LT Debt571.41508.9928.0627.137.958.396.620.000.00
Accounts Payable106.4799.82104.46107.8367.5726.7931.1722.5728.54
Income Tax Payable7.551.272.545.860.230.370.130.01-
Other Current Liabilities570.52330.0382.9441.9738.3829.0615.9521.910.00
Total Current Liabilities1,255.95940.09218.00182.79114.1264.6153.8744.4928.54
Long Term Debt452.46378.04683.63515.43111.41104.1434.480.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities11.307.526.44------
Other Liabilities1.325.18164.86183.743.373.871.020.000.00
Total Liabilities1,721.031,330.831,072.93881.96228.90172.6289.3744.4928.54
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-191.23-109.46-160.94281.061,004.871,026.20670.26320.14224.80
Total Shareholders Equity-191.23-109.46-160.94281.061,004.871,026.20670.26320.14224.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-191.23-109.46-160.94281.061,004.871,026.20670.26320.14224.80
Total Liabilities & Stockholders Equity1,529.801,221.37911.981,163.021,233.771,198.83759.63364.63253.34
Book Value Per Share-3.12-1.83-2.845.0217.7019.0913.977.606.08
Tangible Book Value Per Share-3.19-1.90-2.934.9217.5918.9613.897.505.96
Price to Book Ratio10.26-75.75-91.6015.437.608.749.968.256.10
Return on Assets-18.71-38.34-50.17-51.15-37.28-48.77-43.41-49.67-61.59
Return on Equity---866.68-95.33-44.64-56.31-49.28-56.33-67.99
Return on Invested Capital-98.51-152.27-99.58-76.95-40.62-42.25-34.62-47.94-62.16
Quick Ratio0.760.842.504.637.2814.0212.747.538.61
Current Ratio1.041.173.565.398.0314.0212.747.538.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income858.27-257.35-408.97-520.50-612.92-453.38-477.60-244.01-153.48
Depreciation20.7719.9719.1620.4418.8718.1910.777.491.04
Other Funds (Non Cash)-450.43214.36172.9696.3692.65-0.65158.3735.06-13.32
Funds from Operations432.49-19.26-215.30-397.39-501.40-435.84-308.46-201.47-165.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-26.7880.08-115.91-107.88-19.57-57.82-1.104.562.01
Cash from Operating Activities405.7160.83-331.21-505.27-520.97-493.65-309.56-196.92-163.75
Capital Expenditures-16.88-9.58-1.54-2.64-15.23-28.64-24.57-5.77-3.12
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.001.030.0610.020.005.760.00-
Purchase or Sale of Investments0.000.007.95312.3070.09-102.06-313.150.000.00
Purchase of Investments0.000.000.000.00-224.74-279.21-613.020.000.00
Sale Or Maturity of Investments0.000.007.95312.30294.83177.16299.870.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources1.560.000.000.000.000.000.000.000.00
Cash from Investing Activities-15.32-9.587.44309.7164.88-130.70-331.96-5.77-3.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.8278.64347.3711.12-105.26422.93692.45556.97239.80
Repurchase of Common Pref Stock-120.74-19.630.000.00-110.67-25.540.000.000.00
Sale of Common Pref Stock129.5698.27347.3711.125.42448.47692.45556.97239.80
Proceedsfrom Stock Options-0.150.00314.360.000.00434.83692.45556.97239.80
Issuance or Reduction of Debt, Net--24.78132.82147.31528.93-0.000.000.00
Change in Long Term Debt----528.94-0.000.000.00
Issuance of Long Term Debt----528.94-0.000.000.00
Reduction of Long Term Debt------0.000.000.00
Net Financing Active Other Cash Flow-15.20-12.860.00-1.960.000.000.000.000.00
Other Financing Activities Uses-15.20-12.860.00-1.960.000.000.000.000.00
Cash from Financing Activities-41.6641.00480.19145.19417.00415.33687.01552.45239.80
Exchange Rate Effect19.33-28.4924.63-6.5037.5145.61-60.988.6724.41
Net Change in Cash368.0563.76181.05-56.87-1.58-163.41-15.49358.4397.34
Free Cash Flow388.8351.25-332.75-507.91-536.19-521.67-332.20-202.69-166.88
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow46.86252.17-------
Deferred Taxes & Investment Tax Credit-3.771.546.300.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments928.66660.00723.51633.43579.94559.46
Short Term Receivables256.22226.53185.21173.02142.2982.98
Inventories355.08362.18354.14354.88356.12316.58
Other Current Assets49.7044.4439.6034.5640.2836.37
Total Current Assets1,589.661,293.161,302.451,195.891,118.63995.39
Net Property, Plant & Equipment155.13156.60172.03119.57109.8099.86
Total Investments and Advances34.8527.1538.2033.2640.9744.22
Intangible Assets4.214.254.364.404.454.22
Deferred Tax Assets799.48795.48----
Other Assets0.000.000.000.000.000.00
Total Assets2,613.612,308.181,529.801,356.831,277.031,146.57
Short Term Debt Incl. Current Port. of LT Debt74.81588.26571.41566.68542.73529.25
Accounts Payable118.8190.55106.4792.36110.0191.14
Income Tax Payable14.488.997.551.890.831.70
Other Current Liabilities323.41610.45570.52498.19443.98334.44
Total Current Liabilities531.511,298.261,255.951,159.121,097.55956.53
Long Term Debt439.76444.87452.46389.36387.59385.97
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--11.3012.0811.268.35
Other Liabilities0.002.811.320.810.810.75
Total Liabilities971.271,745.941,721.031,561.371,497.221,351.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,642.34562.24-191.23-204.54-220.18-205.03
Total Shareholders Equity1,642.34562.24-191.23-204.54-220.18-205.03
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,642.34562.24-191.23-204.54-220.18-205.03
Total Liabilities & Stockholders Equity2,613.612,308.181,529.801,356.831,277.031,146.57
Book Value Per Share25.019.05-3.12-3.35-3.64-3.40
Tangible Book Value Per Share24.948.98-3.19-3.42-3.71-3.47
Price to Book Ratio10.26-73.42-63.70-54.68-50.82-85.21
Return on Assets44.5533.69-18.46-19.86-28.10-36.49
Return on Equity121.87325.80----
Return on Invested Capital11.5673.11-14.95-38.56-26.31-55.04
Quick Ratio2.320.720.760.730.690.71
Current Ratio2.991.001.041.031.021.04

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income235.94736.28-38.03-75.93-51.69-99.59
Depreciation5.284.945.545.015.254.78
Other Funds (Non Cash)35.83-672.0767.87117.948.5026.61
Funds from Operations277.0669.1539.2847.01-37.94-68.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital50.46-78.1846.20-45.2628.4653.14
Cash from Operating Activities327.52-9.0385.471.76-9.48-15.06
Capital Expenditures-3.70-9.02-3.92-0.24-4.97-0.74
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.441.120.000.000.000.00
Cash from Investing Activities-3.27-7.90-3.92-0.24-4.97-0.74
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-38.47-23.6717.5753.3813.84-3.75
Repurchase of Common Pref Stock-59.55-60.670.09-0.61-1.41-18.31
Sale of Common Pref Stock21.0837.0017.4853.9915.2514.56
Proceedsfrom Stock Options-0.150.000.000.000.000.00
Issuance or Reduction of Debt, Net-9.40-10.04-7.87-7.98-6.47-3.23
Net Financing Active Other Cash Flow-5.47-9.380.06-0.40-0.92-11.99
Other Financing Activities Uses-5.47-9.380.06-0.40-0.92-11.99
Cash from Financing Activities-53.34-43.099.7645.016.45-18.97
Exchange Rate Effect7.769.46-1.713.81-22.43-9.03
Net Change in Cash278.67-50.5789.6150.34-30.43-43.80
Free Cash Flow323.81-18.0681.561.52-14.45-15.80
Price to Free Cash Flow46.86291.84247.80---

Revenue breakdown

Pharmaceutical Preparations2024: 393.45M 2025: 812.25M
Europe2024: 133.44M 2025: 136.42M
Rest of world2024: 7.78M 2025: 59.55M
United States2024: 252.22M 2025: 616.28M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.62%3.0M64.9M699.82K
2026-10-154.83%3.1M64.9M675.99K
2026-09-305.37%3.5M64.9M640.77K
2026-09-156.10%4.0M64.9M693.17K
2026-08-316.48%4.2M64.9M653.64K
2026-08-145.68%3.7M64.9M674.15K
2026-07-315.53%3.4M61.6M682.59K
2026-07-155.04%3.1M61.6M767.60K
2026-06-305.32%3.3M61.6M781.29K
2026-06-153.23%2.0M61.6M628.98K
2026-05-292.79%1.7M61.6M661.43K
2026-05-152.80%1.7M61.6M680.56K
2026-04-304.60%2.8M61.6M717.35K
2026-04-156.01%3.7M60.8M675.27K
2026-03-316.08%3.7M60.8M675.05K
2026-03-136.33%3.9M60.8M714.26K
2026-02-276.36%3.9M60.8M722.08K
2026-02-136.25%3.8M60.8M711.61K
2026-01-304.79%2.9M60.5M664.44K
2026-01-155.23%3.2M60.5M611.94K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call150105.5109.70.002.3300.000.000.952-0.5370.040
call155100.3104.773.802.2111.000.000.950-0.5310.042
call16095.4099.700.002.0940.000.000.947-0.5250.044
call16590.4094.700.001.9820.000.000.944-0.5190.045
call17085.4089.700.001.8720.000.000.941-0.5120.047
call17580.4084.7057.601.7640.000.000.938-0.5050.049
call18075.6079.8052.651.6791.000.000.934-0.4980.052
call18570.4074.800.001.5760.000.000.929-0.4980.055
call19065.4069.800.001.4740.000.000.925-0.4890.057
call19560.5064.800.001.3750.000.000.919-0.4870.061
call20055.5059.9052.301.2931.000.000.913-0.4760.064
call21045.7050.000.001.1140.000.000.897-0.4660.072
call22036.8040.2032.100.9393.000.000.880-0.4370.081
call23027.3030.8031.500.8168001.000.834-0.4680.100
call24019.3022.1018.940.7202800.000.776-0.4490.121
call25011.9014.6013.500.6532850.000.644-0.5150.150
call2605.207.907.750.55959.004.000.476-0.5180.161
call2701.854.003.500.53741.0023.000.305-0.4350.141
call2800.102.752.000.61316.001.000.206-0.3970.115
call2900.003.301.350.75634.000.000.181-0.4520.107
call3000.002.850.750.9791040.000.190-0.6010.111
call3100.002.600.001.1000.000.000.171-0.6310.104
call3200.002.500.501.0812.000.000.123-0.4970.083
call3300.002.450.081.1841380.000.113-0.5120.078
call3400.002.350.001.2690.000.000.103-0.5150.073
call3500.002.350.001.5110.000.000.126-0.7040.085
call3600.052.300.001.4500.000.000.092-0.5410.067
call3700.002.250.001.6980.000.000.115-0.7440.079
call3800.003.500.001.5820.000.000.084-0.5540.063
put1500.002.150.712.5981.000.00-0.062-0.7140.050
put1550.002.150.002.2040.000.00-0.050-0.5080.042
put1600.002.150.002.0920.000.00-0.052-0.5010.044
put1650.002.150.002.2250.000.00-0.073-0.6860.056
put1700.002.150.001.8730.000.00-0.058-0.4880.048
put1750.002.150.051.76810.000.00-0.062-0.4800.050
put1800.002.150.551.8802.000.00-0.085-0.6540.064
put1850.002.201.351.7711.000.00-0.090-0.6420.066
put1900.052.201.801.48311.000.00-0.074-0.4670.057
put1950.002.250.631.5713.000.00-0.103-0.6280.073
put2000.002.250.731.46617.000.00-0.109-0.6130.077
put2100.002.351.001.10920.000.00-0.102-0.4430.072
put2200.002.551.100.8402490.00-0.103-0.3350.072
put2300.053.001.680.7972121.00-0.166-0.4420.100
put2402.153.302.650.6232801.00-0.223-0.4220.120
put2503.105.604.400.56226.003.00-0.356-0.4870.150
put2608.5010.409.200.5681.001.00-0.524-0.4890.161
put27013.7016.600.000.5460.000.00-0.695-0.4090.141
put28022.1024.700.000.5790.000.00-0.794-0.3660.115
put29031.4034.000.000.6490.000.00-0.824-0.4150.104
put30041.0045.400.000.9300.000.00-0.845-0.4520.096
put31050.9055.000.001.0140.000.00-0.864-0.4620.088
put32060.8065.000.001.1310.000.00-0.878-0.4720.082
put33070.7074.900.001.2290.000.00-0.888-0.4850.077
put34080.7085.000.001.3450.000.00-0.897-0.4860.072
put35090.6094.800.001.4170.000.00-0.903-0.5020.069
put360100.61050.001.5390.000.00-0.909-0.5070.066
put370110.6114.90.001.6150.000.00-0.914-0.5100.063
put380120.5124.90.001.7020.000.00-0.917-0.5210.061

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-16SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-04-14SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-10SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900872.90K2
2026-08492.65K100
2026-070000
2026-0621.90K100
2026-05262.51K34.64M1
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.16.55%
T. Rowe Price Investment Management, Inc.10.88%
Avoro Capital Advisors LLC8.23%
WESTFIELD CAPITAL MANAGEMENT CO LP7.73%
Jupiter Topco LLC5.87%
FMR LLC5.25%
Artisan Partners Limited Partnership4.24%
BlackRock, Inc.3.56%
Capital International Investors3.20%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.02%

Funds

Fund% owned
Franklin Convertible Securities Fund41.54%
T. Rowe Price Capital Appreciation Fund5.42%
Putnam Convertible Securities Fund4.58%
MFS Mid Cap Growth Fund1.94%
VANGUARD HEALTH CARE FUND1.77%
Franklin Dynatech Fund1.61%
Growth Fund of America1.36%
JNL/T. Rowe Price Capital Appreciation Fund 1.28%
Ultra Fund1.07%
T. Rowe Price Mid-Cap Growth Fund, Inc.1.03%

OakChart. ASND. Cached 15 minutes.